SIRT3 and Hepatic steatosis: Sirt3 overexpression effectively decreased body weight gain, serum AST and ALT levels and intrahepatic TG content, ameliorated hepatic steatosis and reversed mitochondrial structural damage (Fig. 6b–e) in HFD-fed Hint2−/− mice.